Extensive small cell lung cancer: trials of Indiana University and the Hoosier Oncology Group

Research output: Contribution to journalArticle

Abstract

Significant advances in the therapy of extensive SCLC have occurred during the past two decades. The first major step involved the incorporation of active single agents into combination chemotherapeutic regimens, such as CAV. During the past decade the platinum compounds (cisplatin, carboplatin) and the epipodophylotoxins (etoposide, teniposide) also have been included in induction and salvage regimens for patients with SCLC. More recently, trials in previously untreated or minimally treated patients have revealed activity of several compounds such as ifosfamide and teniposide, as well as a potentially emerging role for chronic oral administration of etoposide. Numerous trials are currently being conducted by the HOG and others, and it is hoped that their results will elucidate the optimum role of ifosfamide and daily oral etoposide therapy in SCLC. Clearly, carefully designed prospective, randomised trials are necessary to weigh accurately potential benefits against the cost, morbidity, and mortality of treatments.

Original languageEnglish
JournalLung Cancer
Volume9
Issue numberSUPPL. 1
DOIs
StatePublished - 1993

Fingerprint

Small Cell Lung Carcinoma
Etoposide
Teniposide
Ifosfamide
Platinum Compounds
Carboplatin
Cisplatin
Cost-Benefit Analysis
Oral Administration
Therapeutics
Morbidity
Mortality

Keywords

  • Etoposide
  • Ifosfamide
  • Small cell lung cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Extensive small cell lung cancer : trials of Indiana University and the Hoosier Oncology Group. / Loehrer, Patrick; Ansari, Rafat; Einhorn, Lawrence.

In: Lung Cancer, Vol. 9, No. SUPPL. 1, 1993.

Research output: Contribution to journalArticle

@article{dde8c47245d24b0292dc7823ab8d2973,
title = "Extensive small cell lung cancer: trials of Indiana University and the Hoosier Oncology Group",
abstract = "Significant advances in the therapy of extensive SCLC have occurred during the past two decades. The first major step involved the incorporation of active single agents into combination chemotherapeutic regimens, such as CAV. During the past decade the platinum compounds (cisplatin, carboplatin) and the epipodophylotoxins (etoposide, teniposide) also have been included in induction and salvage regimens for patients with SCLC. More recently, trials in previously untreated or minimally treated patients have revealed activity of several compounds such as ifosfamide and teniposide, as well as a potentially emerging role for chronic oral administration of etoposide. Numerous trials are currently being conducted by the HOG and others, and it is hoped that their results will elucidate the optimum role of ifosfamide and daily oral etoposide therapy in SCLC. Clearly, carefully designed prospective, randomised trials are necessary to weigh accurately potential benefits against the cost, morbidity, and mortality of treatments.",
keywords = "Etoposide, Ifosfamide, Small cell lung cancer",
author = "Patrick Loehrer and Rafat Ansari and Lawrence Einhorn",
year = "1993",
doi = "10.1016/0169-5002(93)90004-H",
language = "English",
volume = "9",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Extensive small cell lung cancer

T2 - trials of Indiana University and the Hoosier Oncology Group

AU - Loehrer, Patrick

AU - Ansari, Rafat

AU - Einhorn, Lawrence

PY - 1993

Y1 - 1993

N2 - Significant advances in the therapy of extensive SCLC have occurred during the past two decades. The first major step involved the incorporation of active single agents into combination chemotherapeutic regimens, such as CAV. During the past decade the platinum compounds (cisplatin, carboplatin) and the epipodophylotoxins (etoposide, teniposide) also have been included in induction and salvage regimens for patients with SCLC. More recently, trials in previously untreated or minimally treated patients have revealed activity of several compounds such as ifosfamide and teniposide, as well as a potentially emerging role for chronic oral administration of etoposide. Numerous trials are currently being conducted by the HOG and others, and it is hoped that their results will elucidate the optimum role of ifosfamide and daily oral etoposide therapy in SCLC. Clearly, carefully designed prospective, randomised trials are necessary to weigh accurately potential benefits against the cost, morbidity, and mortality of treatments.

AB - Significant advances in the therapy of extensive SCLC have occurred during the past two decades. The first major step involved the incorporation of active single agents into combination chemotherapeutic regimens, such as CAV. During the past decade the platinum compounds (cisplatin, carboplatin) and the epipodophylotoxins (etoposide, teniposide) also have been included in induction and salvage regimens for patients with SCLC. More recently, trials in previously untreated or minimally treated patients have revealed activity of several compounds such as ifosfamide and teniposide, as well as a potentially emerging role for chronic oral administration of etoposide. Numerous trials are currently being conducted by the HOG and others, and it is hoped that their results will elucidate the optimum role of ifosfamide and daily oral etoposide therapy in SCLC. Clearly, carefully designed prospective, randomised trials are necessary to weigh accurately potential benefits against the cost, morbidity, and mortality of treatments.

KW - Etoposide

KW - Ifosfamide

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0027304546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027304546&partnerID=8YFLogxK

U2 - 10.1016/0169-5002(93)90004-H

DO - 10.1016/0169-5002(93)90004-H

M3 - Article

AN - SCOPUS:0027304546

VL - 9

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - SUPPL. 1

ER -